o**4
发帖数: 35028 | 1 跟诱导ips的方法有关系吧？
病毒诱导的ips跟RNA诱导的ips，immunogenicity应该不一样吧 |
|
f******s
发帖数: 288 | 2 说的是，光查paper了，没想起书来，确实是这么说的。谢啦
但是我想知道的其实就是那个 “到一定量后不再增强” ，那个量的范围有多大。不过
这应该是根据不同immunogen和不同个体决定的。 |
|
o**********y
发帖数: 1041 | 3 Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011). Immunogenicity of
induced pluripotent stem cells. Nature. 2011 |
|
l**********1
发帖数: 5204 | 4 RE: 德艺双馨的楼主
please go to
//www.creativebiomart.net/description_10243_28.htm
You Position: Home >> Antibody >> Polyclonal Antibody >> Rabbit PAb >> Anti-Cdh5 PAb
Anti-Cdh5 PAb
Cat. No.
CPB-133RM
>
Immunogen
Recombinant mouse CDH5 protein.
Antibody Type
Rabbit Polyclonal Antibody.
Ig Type
Rabbit IgG.
Formulation
0.2 μm filtered solution in PBS with 5% trehalose
Preparation
Produced in rabbits immunized with purified, human cell-derived, recombinant mouse CDH5 extracellula... 阅读全帖 |
|
l**********1
发帖数: 5204 | 5 try
//creativebiomart.net/description_54358_27.htm
Cat.No.
CABT-30124HM
Product Overview
Hamster monoclonal antibody to Mouse IGF1.
Antigen Description
The protein encoded by this gene is identical to adenosine deaminase
complexing protein-2, and to the T-cell activation antigen CD26. It is an
intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-
proline dipeptides from the N-terminus of polypeptides.
Clone
SN0000-3G65
Isotype
IgG2
Immunogen
Mouse recombinant IGF1 protein
Hos... 阅读全帖 |
|
n***w
发帖数: 2405 | 6 我也来搭个车来说说自己关于不同条件的fix下的对于IHC的影响。
我是做眼睛的， 我做过如下的比较，
1. Whole globe: O/N fix in 4% PFA
2. Whole globe: 1hour RT in 4% PFA
3. Slit the cornea (more access to PFA) : O/N in 4% PFA
4. Slit the cornea: 1hour RT in 4% PFA
I compared immunogenicity of CD31 and PDGFRb.
Results were:
1>=4>2=3
As for the brain, I usually perfuse and fix with 4% PFA and post-fix in 4%
PFA O/N.
Today I didn't perfuse, I guess I may just leave the brains in 4% PFA for
36hours.
别。 |
|
b******y
发帖数: 627 | 7 GST is 25 KDa and will be more immunogenic than your peptide.
However, you can try GST-peptide-(linker-peptide)n. The bigger n, the lower
yield from E. coli expression. But you probably go to n=5 and still get
substantial protein for mouse injection. |
|
l**********1
发帖数: 5204 | 8 matrix 预言 碰巧了一次
考古一下旧帖吧
Biology版 - Deng Xing-Wang vs. Dong Xinnian
immunogen
2012-05-05 06:20:37
来自: 178.
1
Deng明显比Dong的成就高一个档次，Dong上院士，而Deng一直未上，这是什么天理？再
说，Dong的弟子中也没几个在学术界成功的，而Deng在这方面又比Dong高一个档次。不
知Dong当年作为中国女AP是否也BT?
mab
2012-05-06 11:20:21
来自: 166.
15th floor
就剩deng和chen xuemei了吧
chen太嫩，要上也就deng了
lotkaeuler11
2012-05-06 06:46:34
来自: 152.94.
13th fllor
明年谁上都不奇怪 以下名单里的尚未NAS的
77th Cold Spring Harbor Symposium
on Quantitative Biology
The Biology of Plants
May 30 - June 4, 2012
Speakers:... 阅读全帖 |
|
k****s
发帖数: 1209 | 9 原文在
http://www.skizit.biz/2013/07/21/ecdysone-insect-hormone-an-ind
Ecdysone Insect Hormone Switches on Disease
21 Jul 2013 | ECDYSONE
MORGELLONS:
INSECT HORMONE ECDYSONE TRIGGERS GENETIC CHANGES
TO BUILD NEW HAIR, SKIN, NAILS and CAUSE DISEASES
SkizitGesture-2013
Morgellons is a military grade entomological terror weapon being used to
torture and kill innocent civilians. The medical community has not been
informed about this disease and its complexity keeps it from being properly
identified, ... 阅读全帖 |
|
s****9
发帖数: 932 | 10 我也来说说check－piont blockade。
首先效果并没有楼上说的好。Ipilimumab（anti－CTLA－4） objective response
rate在10%左右（各个地方PhaseIIItrial的效果不一），最好的在MSKCC，也在15%左右
。真正有survival benefit的人群在10%不到，提高的average surivival只有3个月。
考虑到toxicity，这个药目前只在PhaseIII和VI的melanoma上用，就是因为那些病人存
活率不超过5%，等于死马当活马医来治疗。希望能有那么10%不到的人能够中奖且收益
。你说的50%的response，包括了CR，PR，和SD，意义不大。在其他的恶性度比较高的
肿瘤包括NSCLC（肺癌）和prostate cancer Ipilimumab效果不好。其实CTLA－4在老鼠
上效果就只对high immunogenic的肿瘤有效。
anti－PD－1看起来效果比Ipilimumab好，但也只能说稍好，副作用稍小，适用的肿瘤
更多（在NSCLC也有效，renal cell cancer tri... 阅读全帖 |
|
d*p
发帖数: 534 | 11 我说的将近50％反应率是pd-1/pd-l1，具体可以参考nejm上的三篇文章，两个pd-1 抗
体，一个pd-l1 抗体。 在melonoma, lung cancer, renal cancer 上效果都不错，秒
杀过去几十年搞的那些药，如果这都没什么意义，癌症治疗也没啥搞头了。目前看到的
肿瘤生长曲线已经非常的exciting了，有兴趣的可以去读读这三篇文章，看看肿瘤曲线
。从ctla4 到pd-1/pd-l1，不仅仅副作用下降了，疗效也有了大幅度的提高，再等3年
，让我们来看看pd-1/pd-l1 的长期存活率，那时候会更有意义。
anti-ctla-4, 具体可以参考nejm上hodi 的Ipilimumab文章。 在50％存活率这个点比
较，你会发现这个药的疗效也一般，但是重点不在这里，大家可以比较2年半以后，也
就是30个月以后，这个存活曲线的走向。 晚期黑色素瘤,长期存活率提高15%, 10个人
里，可以救活1.5个人，现在有那个药可以做到这点？我觉得这就是重大突破。
虽然pd-1/pd-l1的治疗和pd-l1的表达，以及t cell infiltration 有相关性... 阅读全帖 |
|
f******g
发帖数: 1003 | 12 A vaccine targeting mutant IDH1 induces antitumour immunity
Monoallelic point mutations of isocitrate dehydrogenase type 1 (IDH1) are an
early and defining event in the development of a subgroup of gliomas1, 2, 3
and other types of tumour4, 5, 6. They almost uniformly occur in the
critical arginine residue (Arg 132) in the catalytic pocket, resulting
in a neomorphic enzymatic function, production of the oncometabolite 2-
hydroxyglutarate (2-HG)7, 8, genomic hypermethylation9, 10, 11, genet... 阅读全帖 |
|
|
S**********l
发帖数: 30 | 14 有意者请直接和我联系， 把 CV 和 cover letter (optional) 发 给我：x i n w e i
_ s h e r @merck.com (去掉空格）
https://merck.taleo.net/careersection/merck_external_career_section/
jobdetail.ftl?job=IT+000402&lang=en
Responsibilities include but are not limited to:
• Develop computational methods and pipeline for vaccine design using
NGS data
• Apply the established methods on Merck data and public data and
identify vaccine candidate genes.
Qualifications
Education Minimum Requirement:
• PhD, or met ... 阅读全帖 |
|
l****y
发帖数: 398 | 15 就是筛出来的东东immunogenicity有点高，
[在 wangyi3 (wang3yi) 的大作中提到：]
:phage display 技术早就有了，但是关键的专利掌握在少数几个公司手里，很难开展
:commercial的work， 最近有些专利到期了，新的工作才开展起来。 phage display
筛的好处是可以用high throughput 筛+ next generation sequencing， 效率高，是人
:源性抗体，关键的步奏是phage display 的 library 的建立， |
|
b**********8
发帖数: 349 | 16 Lancet. 2015 Jun 30. pii: S0140-6736(15)60310-5. doi: 10.1016/S0140-6736(15)
60310-5. [Epub ahead of print]
Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter
pylori vaccine in children in China: a randomised, double-blind, placebo-
controlled, phase 3 trial.
Zeng M1, Mao XH2, Li JX3, Tong WD4, Wang B1, Zhang YJ3, Guo G2, Zhao ZJ1, Li
L3, Wu DL5, Lu DS2, Tan ZM3, Liang HY1, Wu C2, Li DH5, Luo P2, Zeng H2,
Zhang WJ2, Zhang JY2, Guo BT2, Zhu FC6, Zou QM7.
Author information
1... 阅读全帖 |
|
l*******i
发帖数: 153 | 17 这取决于你的载体的优点与A细胞在基础研究和临床应用中的重要性。
首先，与目前广泛使用的AAV，retroviral, lentiviral, transposon, episomal,
minicircal等gene delivery tools相比，你的vector有哪些优势：
转染效率如何？
安全性如何？
稳定转染的时间有多长？不会出现transgene silencing?
在deliver大于10kb的transgene cassette 有优势吗？
less immunogenicity?
操作简易程度如何？
成本控制怎样？
如果以上问题都是肯定的，特别是优于viral vector，那么你直接就上nature biotech
或nature methods吧。如果有一半问题是肯定的，那么PNAS档次的应该可以一试；如果
上述三分之一的问题是肯定的，那你就试试molecular therapy。
如果你能拿到病人的细胞，做个correction，在评价一下corrected cell的功能与
efficacy & safety profile，可以试试science tran... 阅读全帖 |
|
S*********e
发帖数: 127 | 18 Thanks,
Immunogenicity of somatic mutations in human gastrointestinal cancers.
Science December 2015
Tran E1, Ahmadzadeh M1, Lu YC1, Gros A1, Turcotte S1, Robbins PF1, Gartner
JJ1, Zheng Z1, Li YF1, Ray S1, Wunderlich JR1, Somerville RP1, Rosenberg SA2
. |
|
发帖数: 1 | 19 immunogen：mouse anti-alpha tubulin, Sigma St. Louis, MO, USA; Cat#: F2168 |
|
S*****a
发帖数: 63 | 20 【 以下文字转载自 Pharmaceutical 讨论区 】
发信人: Somalia (Anti-Pirates), 信区: Pharmaceutical
标 题: Biologics Discovery and Development Positions Available at Abpro Labs in Woburn, MA
关键字: Biologics,Discovery,Development,Antibody,Computational
发信站: BBS 未名空间站 (Wed May 31 20:28:52 2017, 美东)
Multiple Biologics Discovery and Development Positions Available at Abpro
Labs in Woburn, MA
www.abpro-labs.com
To apply please send resume to [email protected]
1. Scientist/Senior Scientist, Antibody Display Technology
... 阅读全帖 |
|
o******u
发帖数: 60 | 21 Card is the old school field of well-evidenced therapy and treatment
However the Neuro part is the used called Dx-only specialty, even now there
are still huge unknowns waiting to reveal.
I have passion in both of them. that's why i ask.
thx for your concern, they aren't overlap much indeed for sure, but I hope I
could find a pattern in relate to both of them.
For example, as there is troponin in heart, is there will be any enzymes in
brain during stroke?
They also have a lot in common, TPA for ... 阅读全帖 |
|
R****0
发帖数: 138 | 22 Rh+ means D antigen present and Rh- represents D antigen absence.
Unsensitized Rh- negative mother should be free of anti-Rh antibodies.
The D antigen is strong immunogenic, Rh- mother can produce anti D antibody
through blood transfusion or placental exposure during pregnancy |
|
a*******o
发帖数: 280 | 23 sounds pretty scary
it is not only the issue of purification, but also glycosylation, folding,
immunogenicity, pharmacokinetics, binding property.
How dare he inject this to human? |
|
c*v
发帖数: 90 | 24 I got their email today and would like to share it with you guys. All
information are also saved in the attachment.
美国华裔医学科学家协会 (NSMS-CAA)
http://www.worldpharma.org/meeting.html
2007 Conferences and Events
美国华裔医学科学家协会 (NSMS-CAA)
2007年大型活动安排
( 欢迎各位积极报名参加!)
http://www.worldpharma.org
按会议时间顺序排列
时间/地点
题目
内容
2007年04月22日
地点: 首都华盛顿
报名参加P-1
美国华裔医学科学家协会 “2007年专家论坛” (1)
-抗生素改造
主办单位: 美国华裔医学科学家协会
New Discovery
Immunogenicity
Engineering Antibody Improvements
Improving Performance
时间/地点
题目
内容
2007年05月11日
地点 |
|
b*******e
发帖数: 724 | 25 小分子药的局限性很大,毒性,DMPK是老大难了,做来做去就是这些问题.现在恐怕只有
ONOCOLOGY做小分子还行.大分子也有大分子的问题,毕竟大部分的MAB都是在MEMBRANE上
作用,TARGET有限.另外IMMUNOGENICITY也是个不可忽视的问题. |
|
k******n
发帖数: 133 | 26 The ADC is a major part of so called mAb v.2.0. The POC is now very well
established. The ker players are Seattle gen and immunogen.
ADC is projected to outpace general mAbs in terms of revenue growth in the
next 5years. Howerver, it remains a very small part of the overall mAb
markets. Its prime time has yet to come. |
|
k******n
发帖数: 133 | 27 The ADC is a major part of so called mAb v.2.0. The POC is now very well
established. The ker players are Seattle gen and immunogen.
ADC is projected to outpace general mAbs in terms of revenue growth in the
next 5years. Howerver, it remains a very small part of the overall mAb
markets. Its prime time has yet to come. |
|
f*********e
发帖数: 1144 | 28 If I remembered correctly (too lazy to 放狗）, the first ADC type drug was
invented by Wyth a decade ago. I wonder why this area has just been picked
up recently??? Just a few ADC drugs (should be less than 10) are in market
from then to present. If the advantage of ADC is really what it is supposed
to be (highly specific/efficacious, prolonged half life, less tox issue/side
effect etc.), then what's the hurdle that prevents the development?
Insufficient understanding of biological mechanism of act... 阅读全帖 |
|
x**********g
发帖数: 327 | 29 请问你们是。。。哪个公司? Seattle? Immunogen? |
|
b****u
发帖数: 2771 | 30 好的targets 必须
1：specific to 癌细胞和组织 )->specificity
2: Expressed on cell surface
3: Internalization rate (这一项涮掉大多数targets）
ADC 所携带toxic agents需要被转运到细胞体内, 在降解中释放出来， 而一般抗体大
多只作用于细胞表面蛋白，抑制protein interaction or signal transduction.
这个参数加上 antibody affinity and target antigen numbers. 基本决定了一个
target 的可选性。
其他如antibody engineering, medicinal chemistry, bioconjugation,
bioanalytical，CMC 都存在很多challenges. 研发ADC 是衡量一个公司综合实力的坐
标， 现在一窝蜂上去的，估计9成是要fail的。 光靠钱是烧不动这个药的。
最近 immunogen 的failed clinical trials可见一斑， 其他的... 阅读全帖 |
|
x**********g
发帖数: 327 | 31 请问你们是。。。哪个公司? Seattle? Immunogen? |
|
b****u
发帖数: 2771 | 32 好的targets 必须
1：specific to 癌细胞和组织 )->specificity
2: Expressed on cell surface
3: Internalization rate (这一项涮掉大多数targets）
ADC 所携带toxic agents需要被转运到细胞体内, 在降解中释放出来， 而一般抗体大
多只作用于细胞表面蛋白，抑制protein interaction or signal transduction.
这个参数加上 antibody affinity and target antigen numbers. 基本决定了一个
target 的可选性。
其他如antibody engineering, medicinal chemistry, bioconjugation,
bioanalytical，CMC 都存在很多challenges. 研发ADC 是衡量一个公司综合实力的坐
标， 现在一窝蜂上去的，估计9成是要fail的。 光靠钱是烧不动这个药的。
最近 immunogen 的failed clinical trials可见一斑， 其他的... 阅读全帖 |
|
|
b******e
发帖数: 3348 | 34 Good company with ADC platform. |
|
|
c******m
发帖数: 884 | 36 over 300 people, not too small... |
|
|
f****6
发帖数: 4472 | 38 药厂确实需要这样的人，不过不用太多（至少是development），因为大部分的工作是
定量不是定性。定量是为了算PK参数，然后设计合适的dosing regimen，这样你才有可
能在临床实验中看到efficacy和尽可能小的side effects。Biologics的off target
toxicity比小分子小多了，但也有immunogenicity等问题。
Discovery不太了解就不评价了，biotech也不太了解。 |
|
|
a******d
发帖数: 955 | 40 ADC已经不行了。。据说很多公司都在减少这方面的投入 |
|
f****6
发帖数: 4472 | 41 ADC限制太多了吧，也很难做，就2-3个公司做的还可以，这么些年了一共也就那么几个
药上市，前景不是很看好。
赞同你说的，单纯的ADC职位很少，单抗是主流啊 |
|
S*****a
发帖数: 63 | 42 Multiple Biologics Discovery and Development Positions Available at Abpro
Labs in Woburn, MA
www.abpro-labs.com
To apply please send resume to [email protected]
1. Scientist/Senior Scientist, Antibody Display Technology
We are seeking an experienced and highly motivated Scientist with strong
hands-on experience in antibody display (phage/yeast) to support discovery
research projects by screening to identify lead candidate therapeutic
antibodies, as well as engineering molecules for improved... 阅读全帖 |
|
p***o
发帖数: 714 | 43 【 以下文字转载自 Stockcafeteria 俱乐部 】
发信人: jhsph07 (银杏), 信区: Stockcafeteria
标 题: Re: ZT: EXEL
发信站: BBS 未名空间站 (Mon Jul 6 11:51:53 2009, 美东)
基本的意思是说， EXEL是做KI的， KI的成功率大概是４０％左右， EXEL的pipeline
上面大概有11个KI， 如果按统计规律， 应该有5个最后会被FDA
批准。
等果实最终成熟大概还需要两年的时间。
Exelixis proves skeptics wrong
Dec 19, 2008
Another company that gives its shareholders reasons to smile is Exelixis, following the mammoth deal with BMS. Exelixis licensed its most advanced compound, XL184, and its early stage RAF inhibitor, XL281 in a de... 阅读全帖 |
|
|
w***y
发帖数: 2537 | 45 【 以下文字转载自 Stock 讨论区 】
发信人: ll111 (Stealth), 信区: Stock
标 题: Events and ER for week August 2-6
发信站: BBS 未名空间站 (Sun Aug 1 22:47:17 2010, 美东)
Monday, Aug. 2
10 a.m.: ISM Manufacturing index on business activity in July, released by
the Institute for Supply Management.
10:15 a.m. Federal Reserve Chairman Ben Bernanke speaking on "challenges for
the economy and state governments."
4 p.m. Treasury Secretary Timothy Geithner speaking on the next steps for
financial reform.
Tuesday, Aug. 3
8:30 a.m.: P... 阅读全帖 |
|
y*****l
发帖数: 5997 | 46 Stocks to Watch at JPMorgan Healthcare Conference
By David Miller Jan 07, 2011 3:00 pm
Next week investors will congregate in California to discuss the future of
the biotech industry. Companies to watch include Exelixis, Medivation, and
Dendreon.
It’s the time of year for the JPMorgan (JPM) Healthcare Conference. The
conference, which runs Monday through Thursday next week in San Francisco,
is the surest place to see everyone in biotech each year. The size of the
crowd at the conference, held at... 阅读全帖 |
|
y*****l
发帖数: 5997 | 47 Stocks to Watch at JPMorgan Healthcare Conference
By David Miller Jan 07, 2011 3:00 pm
Next week investors will congregate in California to discuss the future of
the biotech industry. Companies to watch include Exelixis, Medivation, and
Dendreon.
It’s the time of year for the JPMorgan (JPM) Healthcare Conference. The
conference, which runs Monday through Thursday next week in San Francisco,
is the surest place to see everyone in biotech each year. The size of the
crowd at the conference, held at... 阅读全帖 |
|
f**********g
发帖数: 2252 | 48 来自主题: _pennystock版 - vicl SLOW COW.
Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results
in Melanoma
6 hours 15 minutes ago - PMZ
GlobeNewswireVical Incorporated (Nasdaq:VICL) today announced a new
publication summarizing results from the company's completed trials of
Allovectin-7(R) including systemic responses and an excellent safety profile
in patients with metastatic melanoma. An article published in the January
issue of Immunotherapy1 noted that the U.S. incidence of melanoma is
increasing rapi... 阅读全帖 |
|
f**********g
发帖数: 2252 | 49 来自主题: _pennystock版 - vicl SLOW COW.
Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results
in Melanoma
6 hours 15 minutes ago - PMZ
GlobeNewswireVical Incorporated (Nasdaq:VICL) today announced a new
publication summarizing results from the company's completed trials of
Allovectin-7(R) including systemic responses and an excellent safety profile
in patients with metastatic melanoma. An article published in the January
issue of Immunotherapy1 noted that the U.S. incidence of melanoma is
increasing rapi... 阅读全帖 |
|
v**********m
发帖数: 5516 | 50 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
